Safety study of B10-FC in adults with and without COVID-19
Part of Infections, Lungs & breathing clinical trials.
This trial tests a new drug called B10-FC in two groups: healthy volunteers and people recently diagnosed with mild-to-moderate COVID-19. It aims to check the drug's safety, how the body processes it, and how the immune system responds. The results will help decide if the drug should be studied further.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 45 years old.
- You must be either healthy (stage 1) or have a recent, mild-to-moderate case of COVID-19 with at least 2 symptoms (stage 2).
- You must agree to use effective birth control during the study.
- You must be able to make all study visits.
- You must not be pregnant or breastfeeding.
- You must not have certain medical conditions like serious allergies, autoimmune diseases, or a weakened immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of COVID-19 booster vaccine that targets a protein to help your immune system. It's for people who already had a primary vaccine series and at least one mRNA booster, with the last booster at least 6 months ago.
This trial tests an investigational drug called MDX2301 to see if it's safe in healthy adults and in adults who are at higher risk for severe COVID-19. Higher risk means you have conditions like asthma, diabetes, heart disease, or other listed health issues.
This study looks at how the immune system in the body responds to different COVID-19 virus variants. It may help improve how COVID-19 is diagnosed by comparing people who are currently infected and those who are not.
This study looks at how the body's immune system reacted to COVID-19 in people who had either severe or mild cases. The goal is to learn more about a specific part of the immune response (called IFN-I) to better understand the disease.
This trial studies people with mild to moderate COVID-19 symptoms to better understand and help “post-COVID” condition (ongoing effects after infection). You may be eligible if you’re an adult with a recent confirmed COVID-19 test and you agreed to take part.
This Phase 2 study tests a booster vaccine made from a COVID-19 protein (XBB + prototype) to help your immune system respond better. You may be able to join if you’re an adult who is due for a booster and meets health and safety screening checks.
Hear when a new COVID-19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.